Clinical trials recruiting for NASH
218
Recruiting trials
40
US states with sites
54
Countries
23%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Efimosfermin alfa | 3 |
| ALN-PNP | 2 |
| ECC4703 | 2 |
| Efruxifermin | 2 |
| Ketogenic diet | 2 |
| Pegozafermin | 2 |
| Pioglitazone | 2 |
| Semaglutide | 2 |
| Survodutide | 2 |
| Tirzepatide | 2 |
| 150g of fat with fructose | 1 |
| 150g of fat with glucose | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 24 |
| Texas | 20 |
| Florida | 18 |
| New York | 17 |
| Ohio | 16 |
| Virginia | 16 |
| Missouri | 15 |
| Arizona | 14 |
| Louisiana | 14 |
| North Carolina | 13 |
| Indiana | 11 |
| Minnesota | 11 |
Top cities
San Antonio, Texas 17New York, New York 16Miami, Florida 15Richmond, Virginia 14Austin, Texas 13Houston, Texas 13Brownsville, Texas 11Los Angeles, California 11Tucson, Arizona 11Chandler, Arizona 10
Self-screener
Recruiting trials
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
- A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
- A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
- A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
- A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
- A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
- A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Accurate Point of Care Liver Disease Diagnostics (Phase 2)
- Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
- AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
- An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
- Androgens and NAFLD Longitudinal Cohort Study
- Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
- Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
- Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
- BeijngFH Health Cohort Study
- Bicalutamide Therapy in Young Women With NAFLD and PCOS
- Biomarkers in the Diagnosis and Prognosis of NAFLD
- Blood Collection Biorepository for Liver Disease Research
- CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
- COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
- Cardiac Dysfunction in Patients with Fatty Liver Disease
- Cardiovascular Risk in Children With Chronic Conditions Study
- Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
- Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis
- Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
- Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
- Cold-induced Brown Fat Activation and Hepatic Steatosis
- Comorbidities Resolution After MGB Surgery and Change in Body Composition
- Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
- Comparison of ALD, NASH, and Healthy Control Patients
- Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
- Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
- Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials
- Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
- Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
- Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Digital Early Warning System for Acute Lung Injury in Liver Surgery
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Digoxin In NASH (CODIN)
- Dihydroartemisinin for MAFLD
- Duodenal pulsENDO as an Early Treatment for Type 2 DM
- Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
- Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
- Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
- Effect of CoQ10 on the Outcome of MAFLD Patients
- Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
- Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
- Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
- Effect of Insulin Lowering on Lipogenesis
- Effect of Low Valine Diet on Body Weight and Metabolic Parameters
- Effect of Timed-Restricted Eating on Metabolic Health
- Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
- Effectiveness of Bariatric Surgery for NAFLD/NASH
- Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
- Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
- Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
- Effects of VLCKD in Metabolic Syndrome
- Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
- Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
- Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
- Efficacy and Safety of Rifaximin in Treating MAFLD
- Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
- Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
- Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
- Establishment of NAFLD Cohort and Development of Fibrosis Markers
- Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
- European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
- Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
- Evaluating the Pharmacokinetics and Safety of Miricorilant
- Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
- Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.
- Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Evaluation of Risk of hEpatocellular Carcinoma
- Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
- Exploratory Study of MRI Biomarkers of NASH
- Fatty Liver Disease in Nordic Countries
- Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
- Fibrosis Lessens After Metabolic Surgery
- Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
- Fructose and Liver Diseases in Youth: Help Them FLY
- Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Related conditions
Trials recruiting for NASH often also study these conditions. Each links to its own recruiting-trial list.
Obesity 1512Type 2 diabetes 891Non - Alcoholic Steatohepatitis 15Fatty Liver 17Liver Fibrosis 16Non-Alcoholic Fatty Liver Disease (NAFLD) 10Fatty Liver Disease 10MASLD 15Hepatitis B 147NASH (Nonalcoholic Steatohepatitis) 8
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for NASH trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.